DAIC

JULY 10, 2024

Findings from an observational analysis of ARISE-HF trial participants, newly-published in the Journal of the American College of Cardiology, JACC, shed light on the racial and ethnic disparities in diabetic cardiomyopathy (DbCM), which researchers note may have the potential to inform clinical practice, interventions, and policies. Image courtesy: Getty Images christine.book Wed, 07/10/2024 - 12:02 July 10, 2024 — Findings from an observational analysis of ARISE-HF trial participants, newly-pub

Cardiomyopathy 113

Cardiomyopathy Diabetes Health Disparities Exercise 113

Heart BMJ

JULY 10, 2024

Clinical introduction A woman in her 60s with non-obstructive coronary artery disease, aortic valve replacement and aortic arch repair, chronic diastolic heart failure and paroxysmal atrial fibrillation (AF) and flutter (AFL), presented with 3 days of sustained palpitations that felt similar to prior episodes of AF/AFL. She was euvolemic, haemodynamically stable, with a regular rhythm.

Tachycardia 102

Tachycardia Aortic valve Coronary Artery Disease Atrial Fibrillation 102

DAIC

JULY 10, 2024

Getty Images mtaschetta-millane Wed, 07/10/2024 - 08:51 July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc. , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced European Patent EP3244896 has been granted by the European Patent Office (EPO) covering use of brilaroxazine for the treatment of PH, adding to its existing patent protection in key ma

Pulmonary 111

Pulmonary Hypertension Pharmacology Biomarkers 111

Heart BMJ

JULY 10, 2024

Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR). Despite improvements in outcomes, older adults with competing comorbidities and geriatric syndromes have suboptimal quality of life outcomes, highlighting the cumulative vulnerability that persists despite val

Aortic valve 98

Aortic valve Aortic Quality of Life TAVR 98

DAIC

JULY 10, 2024

In a room of 20 people, it’s likely that about 10 of them, or half, will presently have some form of cardiovascular disease (CVD). CVD is among the most prevalent diseases in the U.S., and strokes and other CVDs are on the rise globally. One report projects a 50% increase in stroke-related deaths by 2050, with 10 million dying annually. Atrial fibrillation (AFib) cases have also surged, doubling from 28.3 million in 1990 to 56.7 million in 2019.

Technology 106

Technology Best Practices AFIB Patient Care 106

Medical Xpress - Cardiology

JULY 10, 2024

Cardiovascular disease often culminates in heart failure, a hallmark of which is fibrosis, a form of tissue scarring. Cardiac fibrosis initially repairs damaged heart tissue, but it can quickly become excessive and pathological. Identifying the mechanisms behind fibrosis is a focal point in cardiovascular research, and now scientists at the Lewis Katz School of Medicine at Temple University have discovered a critical genetic mechanism driving the process—and they have identified a novel target f

Heart Failure 96

Heart Failure Cardiovascular Disease Research 96

DAIC

JULY 10, 2024

mtaschetta-millane Wed, 07/10/2024 - 09:02 July 10, 2024 — CellProthera , a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by CellProthera , as well as plans to continue the relationship into Pha

Myocardial Infarction 105

Myocardial Infarction Heart Failure Heart Attack Heart attacks 105

HCPLive

JULY 10, 2024

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

Diabetes 95

Diabetes 95

Medical Xpress - Cardiology

JULY 10, 2024

Obstructive sleep apnea (OSA) is linked to an increased risk of cardiovascular disease in adults, even those younger than 40, researchers at UT Southwestern Medical Center found.

Heart Disease 85

Heart Disease Cardiovascular Disease Research 85

CardiacWire

JULY 10, 2024

If it seems like your patients are coming from a lot further away these days, that might because nearly half of U.S. counties don’t have a single cardiologist working there. Researchers from Brigham and Women’s Hospital teamed up with GoodRx to analyze data from all 3,143 counties in the US, finding that 46.3% of U.S. counties don’t have a single cardiologist, and this regional cardiologist imbalance often results in… Much Longer Patient Drives – The 22M people who live in these “car

Hospital 64

Hospital Research Outcomes 64

Becker's Hospital Review - Cardiology

JULY 10, 2024

Women age 65 or older who underwent coronary artery bypass grafting, have a higher mortality rate than men and are more likely to be treated at "low-quality hospitals", according to a national study led by researchers from the University of Michigan and published July 10 in JAMA Network Open.

Coronary Artery Bypass Graft 64

Coronary Artery Bypass Graft Hospital Research 64

Heart BMJ

JULY 10, 2024

Learning objectives Understand atherosclerotic cardiovascular disease (ASCVD) risk scores and how and when to use them. Appreciate the differences among the major risk assessment models and select the best tool for each patient. Identify traditional and newer risk factors associated with ASCVD. Appreciate the future of large-model risk prediction calculators and individualised decision-making tools.

Cardiovascular Disease 64

Cardiovascular Disease Risk Factors 64

Science Daily - Heart Disease

JULY 10, 2024

Cardiovascular disease often culminates in heart failure, a hallmark of which is fibrosis, a form of tissue scarring. Cardiac fibrosis initially repairs damaged heart tissue, but it can quickly become excessive and pathological. Identifying the mechanisms behind fibrosis is a focal point in cardiovascular research, and now scientists discovered a critical genetic mechanism driving the process -- and they have identified a target for reversing it.

Heart Failure 63

Heart Failure Research Cardiovascular Disease 63

Science Daily - Stroke

JULY 10, 2024

New research identifies novel path to protecting the brain from stroke-induced damage.

Stroke 91

Stroke Strokes Research 91

HCPLive

JULY 10, 2024

In this interview, Chovatiya discussed the recent FDA approval of roflumilast cream 0.15% for patients with eczema aged 6 years and older.

69

69

Med Page Today

JULY 10, 2024

(MedPage Today) -- For patients with chronic heart failure (HF) who have persistent congestion despite high doses of oral loop diuretics, the right way to intensify diuretics in the outpatient setting may be narrowed, based on a small randomized.

Outpatient 59

Outpatient Heart Failure 59

HCPLive

JULY 10, 2024

Findings from a phase 2b study demonstrate fazirsiran’s dose-dependent impact on Z-AAT concentrations and histological measures of liver disease in patients with AATD.

59

59

American College of Cardiology

JULY 10, 2024

The Centers for Medicare and Medicaid Services (CMS) has released the proposed 2025 Medicare Physician Fee Schedule (PFS). Of note, the PFS conversion factor has been updated from $33.2875 to $32.3562, a 2.80% cut. The overall reimbursement for cardiovascular services is projected to remain flat compared with 2024, with changes to policies and individual services roughly balancing out.

CMS 63

CMS Medicare Reimbursement Medicaid 63

Medical Xpress - Cardiology

JULY 10, 2024

Routine electrocardiogram (ECG) screening may help to prevent cardiovascular disease (CVD) events, according to a study published online July 1 in JAMA Internal Medicine.

Cardiovascular Disease 54

Cardiovascular Disease Electrocardiogram 54

American College of Cardiology

JULY 10, 2024

What is the outcome of contemporary revascularization strategies in patients presenting with myocardial infarction (MI) and multivessel coronary artery disease (CAD)?

Coronary Artery Disease 63

Coronary Artery Disease Myocardial Infarction Outcomes Article 63

HCPLive

JULY 10, 2024

Prior authorizations for the anti-VEGF therapies aflibercept, ranibizumab, and bevacizumab were almost always approved but delayed care for most patients.

59

59

Becker's Hospital Review - Cardiology

JULY 10, 2024

Female and older cardiologists receive lower average ratings in online reviews compared to other cardiologists, a recent study found.

64

64

HCPLive

JULY 10, 2024

Findings underscore the importance of HCC screening adherence in patients with HCV-related cirrhosis who achieve HCV cure for improving overall survival.

59

59

Cardiovascular Diabetology

JULY 10, 2024

The triglyceride-glucose (TyG) index and its combination with obesity indicators can predict cardiovascular diseases (CVD). However, there is limited research on the relationship between changes in the triglyc.

Cardiovascular Disease 52

Cardiovascular Disease Obesity Research 52

HCPLive

JULY 10, 2024

Approximately 1454 counties with 2 million residents have no cardiologist in the US, primarily affecting rural and socioeconomically disadvantaged areas.

59

59

Cardiovascular Diabetology

JULY 10, 2024

Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME trial in which 7020 people with type 2 diabetes (T2D) and cardiovascular disease [mostly atherosclerotic (ASCVD)] were randomized to empagliflozin or placebo and followed for a median 3.1 years.

Myocardial Infarction 52

Myocardial Infarction Coronary Artery Bypass Graft Outcomes Plaque 52

HCPLive

JULY 10, 2024

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

69

69

Frontiers in Cardiovascular Medicine

JULY 10, 2024

Cardiotoxicity can be defined as “chemically induced heart disease”, which can occur with many different drug classes treating a range of diseases. It is the primary cause of drug attrition during pre-clinical development and withdrawal from the market. Drug induced cardiovascular toxicity can result from both functional effects with alteration of the contractile and electrical regulation in the heart and structural changes with morphological changes to cardiomyocytes and other cardiac cells.

Physiology 52

Physiology Heart Failure Arrhythmia Heart Disease 52

HCPLive

JULY 10, 2024

A study revealed factors linked to gout flare risk included the absence of tophi, younger age, and more. Taking allopurinol over febuxostat or vice versa did not affect flare risk.

52

52

Frontiers in Cardiovascular Medicine

JULY 10, 2024

BackgroundAortic stenosis (AS) in combination with left ventricular outflow tract obstruction (LVOTO) has occasionally been reported. However, making a precise diagnosis and successfully treating this combination is challenging due to the hemodynamic interaction between the two conditions.Case summaryA 56-year-old male patient who had been diagnosed with severe AS and asymmetric left ventricular hypertrophy underwent aortic valve replacement (AVR) and a conventional septal myectomy.

Aortic valve 52

Aortic valve Aortic Bicuspid/Mitral Stenosis 52

Dr. Smith's ECG Blog

JULY 10, 2024

Our latest @stemlyns podcast is an absolute cracker. A chat with @smithECGBlog about all things OMI and artificial intelligence for ECG interpretation. Could be a game changer for many.

52

52

Cardiometabolic Health Congress

JULY 10, 2024

The entire CMHC and cardiometabolic community mourns the loss of Dr. George L. Bakris , an internationally recognized and influential nephrologist and hypertension expert, who passed away on June 15, 2024, at the age of 72. His contributions have left an indelible mark on countless patients and healthcare professionals privileged to work alongside him.

Hypertension 52

Hypertension Education Blood Pressure Kidney Disease 52

Frontiers in Cardiovascular Medicine

JULY 10, 2024

Uromodulin, also referred to as Tamm Horsfall protein (THP), is a renal protein exclusively synthesized by the kidneys and represents the predominant urinary protein under normal physiological conditions. It assumes a pivotal role within the renal system, contributing not only to ion transport and immune modulation but also serving as a critical factor in the prevention of urinary tract infections and kidney stone formation.

Cardiovascular Disease 52

Cardiovascular Disease Biomarkers Physiology 52

Heart BMJ

JULY 10, 2024

Background Enzyme replacement therapy (ERT) may halt or attenuate disease progression in patients with Anderson-Fabry disease (AFD). However, whether left ventricular hypertrophy (LVH) can be prevented by early therapy or may still progress despite ERT over a long-term follow-up is still unclear. Methods Consecutive patients with AFD from the Independent Swiss-Fabry Cohort receiving ERT who were at least followed up for 5 years were included.

40

40

HCPLive

JULY 10, 2024

Study finds women with familial hypercholesterolemia receive less intensive treatment and are less likely to achieve LDL-C goals than men.

59

59

Heart BMJ

JULY 10, 2024

Background Despite restoration of epicardial blood flow in acute ST-elevation myocardial infarction (STEMI), inadequate microcirculatory perfusion is common and portends a poor prognosis. Intracoronary (IC) thrombolytic therapy can reduce microvascular thrombotic burden; however, contemporary studies have produced conflicting outcomes. Objectives This meta-analysis aims to evaluate the efficacy and safety of adjunctive IC thrombolytic therapy at the time of primary percutaneous coronary interven

Myocardial Infarction 52

Myocardial Infarction Thrombolysis STEMI Outcomes 52

American College of Cardiology

JULY 10, 2024

In this week’s View, Dr. Eagle discusses a state-of-the-art review on iron repletion for patients with heart failure and iron deficiency.

Heart Failure 63

Heart Failure Article 63